Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort study.
Shoemark A, Johnson ED, Shuttleworth M, Schwiening M, Hull R, Stobo J, Abo-Leyah H, Finch S, Pollock J, Huang JTJ, Richardson H, Perea L, McIntosh E, Cant E, Galloway R, Choi H, de Soyza A, Spinou A, Ringshausen FC, Lorent N, Mallia P, Johnston SL, Gierlinski M, Goeminne P, Loebinger MR, Hua Gao Y, Chotirmall SH, Dhar R, Haworth C, Altenburg J, Blasi F, Polverino E, Shteinberg M, Strickson S, Cipolla D, Teper A, Fernandez C, Shih VH, Mange K, Singanayagam A, Aliberti S, Sibila O, Long MB, Chalmers JD.
Shoemark A, et al. Among authors: huang jtj.
Lancet Respir Med. 2026 Apr 24:S2213-2600(25)00334-0. doi: 10.1016/S2213-2600(25)00334-0. Online ahead of print.
Lancet Respir Med. 2026.
PMID: 42044645
Free article.